Let’s dig into the relative performance of Abbott Laboratories (NYSE:ABT) and its peers as we unravel the now-completed Q4 ...

Valued at a market cap of $228.3 billion, Abbott Laboratories (ABT) is a global healthcare company that discovers, develops, ...

Abbott’s pulse field ablation system competes with products from Medtronic and Boston Scientific, which also have large ...

Johnson & Johnson and Boston Scientific have also recently made moves to sell their own coronary intravascular lithotripsy ...

Shares of Abbott Laboratories and Reckitt Benckiser fell Friday after a judge ruled a new trial could be heard involving a case on their infant formula products that had already seen a ruling in ...

Abbott Laboratories (NYSE:ABT) recently announced successful outcomes from its TRILUMINATE™ Pivotal trial for the TriClip™ system, showcasing significant improvements in patient outcomes for tricuspid ...

Abbott Laboratories closed 6.08% below its 52-week high of $141.23, which the company reached on March 4th.

Two former Abbott Laboratories employees have sued the company ... She was tasked with creating new processes to prevent poor-quality products from leaving the facility. Mayhew was also on ...

A St. Louis judge has granted a new trial in a case Abbott Laboratories won in the fall, in which a mother alleged that the company’s cow’s milk-based products for premature infants contributed to her ...

Abbott Laboratories (NYSE ... Abbott announced that it earned a CE mark in Europe for its Volt PFA System, a product used to treat people with atrial fibrillation (a common heart disorder).

A St. Louis judge has granted a new trial in a case Abbott Laboratories won in the fall, in which a mother alleged that the company’s cow’s milk-based products for premature infants ...